🕵️ Achieve Life Sciences, Inc. ($ACHV)
SEC insider & ownership activity, last 12 months · CIK 949858 · every row links its SEC filing
Over the last 12 months insiders sold $1.1M with no open-market buying against it. King Thomas Braxton sold $387K in discretionary trades (Sep). No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
0 buyers, $0 (0 lots) · 6 sellers, $1.1M (6 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| King Thomas Braxton | 0 | – | 1 | $387K | Sep 4, 2025 |
| Stewart Richard Alistair | 0 | – | 1 | $378K | Sep 18, 2025 |
| Mark K. Oki | 0 | – | 1 | $146K | Sep 18, 2025 |
| Jacobs Cindy | 0 | – | 1 | $77K | Sep 4, 2025 |
| Xinos Jaime | 0 | – | 1 | $58K | Sep 4, 2025 |
| Wan Jerry | 0 | – | 1 | $39K | Sep 4, 2025 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| TPG GP A, LLC | 12.6% | 13D | Apr 17, 2025 | filing ↗ | |
| James G. Coulter | 12.6% | 13D | Apr 17, 2025 | filing ↗ | |
| Jon Winkelried | 12.6% | 13D | Apr 17, 2025 | filing ↗ | |
| Venbio Global Strategic GP V, LLC | 10.0% | 13D | Apr 15, 2026 | filing ↗ | |
| Venbio Global Strategic Fund V, L.P. | 10.0% | 13D | Apr 15, 2026 | filing ↗ | |
| Paradigm Biocapital Advisors LP | 9.2% | 13G | Apr 24, 2026 | filing ↗ | |
| Paradigm Biocapital Advisors GP LLC | 9.2% | 13G | Apr 24, 2026 | filing ↗ | |
| Senai Asefaw, M.D. | 9.2% | 13G | Apr 24, 2026 | filing ↗ | |
| Franklin Resources, Inc. | 8.3% | 13G | Jul 28, 2026 | filing ↗ | |
| Franklin Advisers, Inc. | 8.3% | 13G | Jul 28, 2026 | filing ↗ | |
| Paradigm Biocapital International Fund Ltd. | 8.1% | 13G | Apr 24, 2026 | filing ↗ | |
| Frazier Life Sciences Public Fund, L.P. | 6.5% | 13G | Apr 24, 2026 | filing ↗ | |
| Fhmlsp, L.P. | 6.5% | 13G | Apr 24, 2026 | filing ↗ | |
| Fhmlsp, L.L.C. | 6.5% | 13G | Apr 24, 2026 | filing ↗ | |
| Alyeska Investment Group, L.P. | 5.6% | 13G | Nov 14, 2025 | filing ↗ | |
| Alyeska Fund GP, LLC | 5.6% | 13G | Nov 14, 2025 | filing ↗ | |
| Anand Parekh | 5.6% | 13G | Nov 14, 2025 | filing ↗ | |
| Venrock Healthcare Capital Partners III, L.P. | 5.2% | 13G | Apr 24, 2026 | filing ↗ | |
| VHCP Co-Investment Holdings III, LLC | 5.2% | 13G | Apr 24, 2026 | filing ↗ | |
| Venrock Healthcare Capital Partners EG, L.P. | 5.2% | 13G | Apr 24, 2026 | filing ↗ | |
| VHCP Management III, LLC | 5.2% | 13G | Apr 24, 2026 | filing ↗ | |
| VHCP Management EG, LLC | 5.2% | 13G | Apr 24, 2026 | filing ↗ | |
| Nimish Shah | 5.2% | 13G | Apr 24, 2026 | filing ↗ | |
| Bong Y. Koh | 5.2% | 13G | Apr 24, 2026 | filing ↗ | |
| Blackrock, Inc. | 5.1% | 13G | Jul 27, 2026 | filing ↗ | |
| VIVO Opportunity, LLC | 5.0% | 13G | Jul 8, 2026 | filing ↗ | |
| VIVO Opportunity Co-Invest (CYCLE 3), L.P. | exited | 13G | Jul 8, 2026 | filing ↗ | |
| VIVO Opportunity Fund Holdings, L.P. | exited | 13G | Jul 8, 2026 | filing ↗ | |
| VIVO Opportunity Co-Invest, L.P. | exited | 13G | Jul 8, 2026 | filing ↗ | |
| VIVO Opportunity Cayman Fund, L.P. | exited | 13G | Jul 8, 2026 | filing ↗ | |
| VIVO Opportunity Cayman, LLC | exited | 13G | Jul 8, 2026 | filing ↗ | |
| Charles B. Johnson | exited | 13G | Jul 28, 2026 | filing ↗ | |
| Rupert H. Johnson, JR. | exited | 13G | Jul 28, 2026 | filing ↗ |
Planned insider sales (Form 144)
No sale notices filed in the last 12 months.
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Charter/bylaw changes (5.03) | Jul 2, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jul 2, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 2, 2026 | filing ↗ |
| Officer/director changes (5.02) | May 29, 2026 | filing ↗ |
| Earnings (2.02) | May 7, 2026 | filing ↗ |
| Officer/director changes (5.02) | May 7, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 7, 2026 | filing ↗ |
| Material agreement (1.01) | Apr 15, 2026 | filing ↗ |
| Unregistered equity sale (3.02) | Apr 15, 2026 | filing ↗ |
| Officer/director changes (5.02) | Apr 15, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Apr 15, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 15, 2026 | filing ↗ |
| Earnings (2.02) | Mar 24, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 24, 2026 | filing ↗ |
| Earnings (2.02) | Nov 6, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 6, 2025 | filing ↗ |
| Officer/director changes (5.02) | Oct 6, 2025 | filing ↗ |
| Officer/director changes (5.02) | Sep 5, 2025 | filing ↗ |
| Earnings (2.02) | Aug 7, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 7, 2025 | filing ↗ |